Wobenzym bei Diabetes

Diabetes 2019 - Erkenntnisse - Ursachen - Lösungen

Nach Koma bei Diabetes mellitus

Study record managers: refer to the Data Element Definitions if submitting registration or results information. The general objective of this project is to examine the impact of Wobenzym PS supplementation on blood markers of inflammation and inflammation gene expression in volunteers with sub-clinical inflammation.

The study will be undertaken according to a double-blind, cross over, randomized, placebo controlled design. The impact of Wobenzym PS on inflammation vs. The two 4-week supplementation will be separated by a 4-week wash out period. Dietary Supplement: Wobenzym PS Placebo Comparator: Placebo During the 4-week of placebo phase, participants will take 6 tablets of placebo: 2 tablets 3 times daily at least 45 minutes before meal.

Talk with your doctor and Wobenzym bei Diabetes members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Search for terms x. Save this study. Warning You have reached the maximum number of saved studies The Effect of Wobenzym PS on Inflammation WO The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Last Wobenzym bei Diabetes Posted : April 2, Study Description. Inflammation is being increasingly recognized as key etiological factor in the development of atherosclerosis and subsequent cardiovascular disease CVD. This pro-atherogenic state is strongly correlated Wobenzym bei Diabetes often found co-segregating among Wobenzym bei Diabetes with obesity and metabolic syndrome.

There is increasing evidence to support the use in clinical practice of these novel markers of atherosclerosis and CVD risk. C-reactive protein CRP has been used extensively as a Wobenzym bei Diabetes marker of acute phase response in clinical practice for decades.

More recently, CRP has also been proposed to be a new cardiovascular biomarker of atherosclerosis and its complications. Wobenzym is an enzyme formula primarily recommended Wobenzym bei Diabetes the treatment of pain and inflammation associated with musculoskeletal disorders.

Several studies in the areas of arthritis and post-surgery have reported the acute anti-inflammatory effects of Wobenzym in terms of changes in CRP. Whether Wobenzym plays a role in managing sub-acute inflammation as well remains to be investigated. Arms and Interventions. During the 4-week of Wobenzym bei Diabetes phase, participants will take 6 tablets of placebo: 2 tablets 3 times daily at least 45 minutes before meal.

Outcome Measures. Eligibility Criteria. Information from the National Wobenzym bei Diabetes of Medicine Choosing to participate in a study is an important personal decision.

Any active gastrointestinal disease Use of anticoagulants or thrombocyte aggregation inhibitors, chemotherapeutic agents, antibiotics, medication for lipids, diabetes, hypertension, inflammation, autoimmune diseases, mood disorders Use of NSAID nonsteroidal antiinflammatory drug Wobenzym bei Diabetes 1 month of entering the study Excessive alcohol consumption more than two drinks by day for men, one for women and active alcoholism; smoking; Wobenzym bei Diabetes use and history of drug abuse; supplements or natural products consumption during the study Pregnant or breastfeeding women.

Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may Wobenzym bei Diabetes the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. More Information. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and Wobenzym bei Diabetes. Sub-clinical Inflammation.

Not Applicable. Study Type :. Actual Enrollment :. Triple Participant, Care Provider, Investigator. Study Start Date :. Actual Primary Completion Date :. Actual Study Completion Date :. Experimental: Wobenzym PS During the 4-week of the Wobenzym supplementation, participants will take 6 tablets of Wobenzym: 2 tablets 3 times daily at least 45 minutes before meal.

Placebo Comparator: Placebo During the 4-week of placebo phase, participants will take 6 tablets of placebo: 2 tablets 3 times daily at least 45 minutes before meal. Inflammation Pathologic Processes Wobenzym.